AnaptysBio Inc

ANAB

Get informed when a big investor buys or sells

Market Cap$1.68B

Close$

Compare to Similar Companies

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
AnaptysBio Inc	-66.6	-	-210%	7.1	21.8

$77.20

Target Price by Analysts

35.5% upsideAnaptysBio Target Price Details

$-14.56

Current Fair Value

125.6% downside

Overvalued by 125.6% based on the discounted cash flow analysis.

Share Statistics

Market cap	$1.68 Billion
Enterprise Value	$1.71 Billion
Dividend Yield	$- (-)
Earnings per Share	$-0.46
Beta	0.4
Outstanding Shares	28,691,000

Return

Return on Equity	-210.14%
Return on Assets	-8.13%
Return on Invested Capital	10.96%

Valuation & Multiples

P/E Ratio	-66.6
PEG	-193.24
Price to Sales	7.12
Price to Book Ratio	-
Enterprise Value to Revenue	7.34
Enterprise Value to EBIT	54.03
Enterprise Value to Net Income	-64
Total Debt to Enterprise	0.16
Debt to Equity	21.76

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date

August 12, 2026

EPS Estimate

$-0.13

Average shareholder expectation

Revenue Estimate

$17.33 M

Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio	0.0000▼ 21.51%
Total Calls	-▼ 100.00%
Total Puts	-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %	16.36%▼ 131.26%
Total Invested	$316.84M▼ 79.57%
Investors Holding	61▼ 149.00%

ESG Score